SCHEMBL697443

SCHEMBL697443

C[C@@]1(C(=O)O)CCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL573927 1.00
SCHEMBL3325667 1.00
Bromide SCHEMBL6632314 0.98 FFAR3 (0.39)
Bromide SCHEMBL14659502 0.98 FFAR3 (0.39)
Hydrochloric Acid SCHEMBL16798066 0.98 FFAR3 (0.39)
Water SCHEMBL25175984 0.98 FFAR3 (0.39)
Hydrochloric Acid SCHEMBL17393208 0.98 FFAR3 (0.39)
Hydrochloric Acid SCHEMBL17393207 0.98 FFAR3 (0.39)
SCHEMBL25372775 0.93 FFAR3 (0.39)
SCHEMBL53553 0.93 FFAR3 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 823 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070294-A Stable vitreous material based on histidine, arginine and glutamic acid amino acids 阵序补丁有限公司 2026-05-19 CN claimed
CN-122055375-A Compounds and methods for treating central nervous system disorders 美国西北大学 2026-05-15 CN claimed
EP-4727654-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP claimed
EP-4727653-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP claimed
EP-4727655-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP claimed
US-12297172-B2 Compositions of trofinetide NEUREN PHARMACEUTICALS LIMITED (NZ) 2025-05-13 US claimed
WO-2025049670-A1 COMPOUNDS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS NORTHWESTERN UNIVERSITY (US) 2025-03-06 WO claimed
US-20250049970-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC (US) 2025-02-13 US claimed
US-20250034210-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC (US) 2025-01-30 US claimed
US-20250011368-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC (US) 2025-01-09 US claimed
US-5658928-A ANTICOAGULANTS, ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENTS,WOUND HEALING AGENTS, OSTEOPOROSIS HOFFMANN-LA ROCHE INC. (US) 1997-08-19 US claimed
US-5534498-A TREATMENT OF PANCREATITIS CORVAS INTERNATIONAL, INC. (US) 1996-07-09 US claimed
EP-0505868-B1 N-Acyl-alpha-aminoacids derivatives HOFFMANN LA ROCHE (CH) 1995-09-13 EP claimed
US-5378712-A Antithrombosis Hoffmann-La Roche Inc (US) 1995-01-03 US claimed
EP-0422937-B1 Fibrinogen receptor antagonists MERCK & CO INC (US) 1994-03-02 EP claimed
WO-1993000108-A1 NOVEL INHIBITORS OF PLATELET AGGREGATION CORVAS INTERNATIONAL, INC. (US) 1993-01-07 WO claimed
EP-0505868-A2 N-Acyl-alpha-aminoacids derivatives F. HOFFMANN-LA ROCHE AG (CH) 1992-09-30 EP claimed
US-5023233-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1991-06-11 US claimed
EP-0411833-A1 Fibrinogen receptor antagonists MERCK & CO. INC. (US) 1991-02-06 EP claimed
US-4482725-A ANGIOTENSIN CONVERTING ENZYME INHIBITOR E. R. SQUIBB & SONS, INC. (US) 1984-11-13 US claimed